Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Procter & Gamble HealthBOM:500126 -5.74%87 Days Inventory is 134.27 as of Mar. 2026, which is 3% below its 10-year median of 138.11. GuruFocus rates BOM:500126 with a GF Score™ of 87/100 and a GF Value™ of ₹6,124.41 (Fairly Valued). The stock has 6 warning signs investors should review. Among 922 Drug Manufacturers companies, Procter & Gamble Health ranks better than 63.67% on this metric.
The historical rank and industry rank for Procter & Gamble Health's Days Inventory or its related term are showing as below:
BOM:500126'
s Days Inventory Range Over the Past 10 Years
Min: 116.12 Med: 138.11 Max: 234.19
Current: 131.96
During the past 13 years, Procter & Gamble Health's highest Days Inventory was 234.19. The lowest was 116.12. And the median was 138.11.
BOM:500126's Days Inventory is ranked better than 63.67% of 922
companies
in the Drug Manufacturers industry
Industry Median: 165.005
vs BOM:500126: 131.96
Inventory Turnover measures how fast the company turns over its inventory within a year.
Procter & Gamble Health's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.68.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Procter & Gamble Health's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.37.
Procter & Gamble Health (BOM:500126) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Procter & Gamble Health's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Procter & Gamble Health's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Procter & Gamble Health Days Inventory Related Terms
Procter & Gamble Health Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Procter & Gamble Health's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Procter & Gamble Health Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Procter & Gamble Health's Days Inventory distribution charts can be found below:
* The bar in red indicates where Procter & Gamble Health's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Procter & Gamble Health (BOM:500126) has a Days Inventory of 134.27 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Procter & Gamble Health and its competitors. This is near median its historical median of 138.11. Over the past decade, Procter & Gamble Health's Days Inventory has ranged from 116.12 to 234.19. According to the industry distribution chart, Procter & Gamble Health ranks #335 out of 922 companies in the Drug Manufacturers industry, placing it in the top 36.3%.
Is Procter & Gamble Health's Days Inventory too high?
Procter & Gamble Health's current Days Inventory of 134.27 is near median its 10-year median of 138.11. Over the past 10 years, this metric has ranged from a low of 116.12 to a high of 234.19. The Drug Manufacturers industry median Days Inventory is 165.01. Procter & Gamble Health's value of 134.27 is 18.6% below this industry median. Based on the distribution chart, Procter & Gamble Health ranks #335 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Procter & Gamble Health has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Procter & Gamble Health's Days Inventory compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Procter & Gamble Health ranks #335 out of 922 companies for Days Inventory. This puts Procter & Gamble Health in the upper half of its industry. The industry median Days Inventory is 165.01. Procter & Gamble Health's value of 134.27 is 18.6% below this benchmark. Historically, Procter & Gamble Health's own Days Inventory has ranged from 116.12 to 234.19 over the past decade. While the company's 10-year median is 138.11 vs. the industry median of 165.01, Procter & Gamble Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 165.01, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Procter & Gamble Health's current Days Inventory of 134.27 is 18.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Procter & Gamble Health and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 165.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Procter & Gamble Health's current Days Inventory is 134.27, which is near median its own 10-year median of 138.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Procter & Gamble Health stock overvalued right now?
Based on GuruFocus' analysis, Procter & Gamble Health (BOM:500126) is currently considered Fairly Valued. The stock's GF Value™ is ₹6,124.41, compared to a current price of ₹6,087.90 — trading 0.6% below its estimated fair value. The current Days Inventory is 134.27, which is near median its 10-year median of 138.11 and 18.6% below the Drug Manufacturers industry median of 165.01. Procter & Gamble Health's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Procter & Gamble Health (BOM:500126), the current Days Inventory is 134.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Procter & Gamble Health (BOM:500126) Overvalued in 2026?
Based on GuruFocus' analysis, Procter & Gamble Health stock appears to be undervalued.
The current stock price of ₹6,087.90 is trading 0.6% below its estimated GF Value™ of ₹6,124.41.
GuruFocus considers Procter & Gamble Health to be Fairly Valued.
Key valuation signals for BOM:500126:
Days Inventory: 134.27 (near median its 10-year median of 138.11)
GF Value™: ₹6,124.41 vs. price of ₹6,087.90 (0.6% below fair value)
Industry Position: 18.6% below the Drug Manufacturers median (#335 of 922)
No single metric tells the full story. See the BOM:500126 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Procter & Gamble Health Ltd is an India based pharmaceutical company engaged in manufacturing and selling of healthcare products, viz., vitamins, minerals and supplements. Patients are end consumers of the products. The Company's distribution channels (direct & indirect), inter alia, include distributors, health care professionals, pharmacies and chemists. Cosome, Evion, Neurobion, Nasivion, Polybion, Livogen and Seven Seas are some of the brands of the company. The geographical segments include sales in India and exports.
87GF Score
Get the complete analysis for BOM:500126
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500126 has been successfully added to your 
